Search Results

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, Human Acellular Vessels at commercial scale, announced the issuance of four new ICD-10-PCS codes by the U.S. Centers for Medicare & Medicaid Services ICD-10 Coordination and Maintenance Committee.

CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency’s Health Plan Management System.

The Centers for Medicare & Medicaid Services revised the National Coverage Determination of allogeneic hematopoietic stem cell transplantation for individuals with myelodysplastic syndromes due to a request for reconsideration prepared by The American Society of Hematology, the American Society for Transplantation and Cellular Therapy®, the National Marrow Donor Program, and the Center for International Blood and Marrow Transplant Research on January 5, 2024.

Invivyd, Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code covering product reimbursement for PEMGARDA.

For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.

Verrica Pharmaceuticals Inc. announced that the Centers for Medicare & Medicaid Services has issued a permanent J-Code for YCANTH™, which is the only FDA-approved treatment for molluscum contagiosum.

Celularity Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code for Biovance® 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap that acts as a scaffold for restoration of functional tissue in partial- and full-thickness, acute and chronic wounds.

Endologix LLC announces that the U. S. Centers for Medicare & Medicaid Services granted a Transitional Pass-Through Payment for the DETOUR System, effective January 1, 2024.

Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming days